Boehringer Ingelheim International GmbH - Company Profile
Powered by 
All the data and insights you need on Boehringer Ingelheim International GmbH in one report.
$295
- Save hours of research time and resources with
our up-to-date Boehringer Ingelheim International GmbH Strategy Report
- Understand Boehringer Ingelheim International GmbH position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Boehringer Ingelheim International GmbH (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, develops and manufactures a wide range of pharmaceuticals for human and animal use.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Boehringer Ingelheim conducts research to develop innovative therapies and vaccines for treatment of unmet medical needs. The company directs its R&D efforts towards advancing the treatment options in the areas of cardiometabolic diseases, oncology, respiratory disorders, and diseases of central nervous system (CNS) and immunology. Major pipeline products include empagliflozin, a SGLT2 inhibitor in Phase III clinical trials indicated for chronic kidney disease and congestive heart failure; BI 764198, a TRPC 6 inhibitor in Phase II for COVID-19 iARDS; BI 1358894, a GlyT1 inhibitor for complete androgen insensitivity syndrome is in Phase III trials; osoresnontrine, a PDE9 inhibitor in Phase II for first episode psychosis and reduction of relapse in schizophrenia; and BI 456906, a GLP1/GCGR agonist in Phase II for obesity. It also evaluates external projects and seeks to pursue joint development activities through partnerships. The company operates an extensive research network with major facilities in Biberach and Ingelheim am Rhiem, Germany; Shanghai, China; Lyon, France; Vienna, Austria; and Ridgefield, Connecticut; Duluth, Georgia; and St. Joseph, Missouri in the US.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer